Skip to main content

FDA Approves Gabapentin Enacarbil for Postherpetic Neuralgia


June 7, 2012 — The US Food and Drug Administration (FDA) has approved gabapentin enacarbil (Horizant, GlaxoSmithKline) extended-release tablets for the management of postherpetic neuralgia in adults.
The drug, approved in April 2011 for the treatment of restless legs syndrome (RLS), is now approved to treat postherpetic neuralgia (PHN) at a dose of 600 mg twice daily, notes a joint statement from GlaxoSmithKline (GSK) and Xenoport Inc.
The drug, a prodrug of gabapentin, was discovered and developed by XenoPort. Gabapentin enacarbil uses the body's nutrient transport mechanisms, through which it is thought to be absorbed into the body, the companies' statement notes. Once absorbed, it is converted to gabapentin and binds to a specific calcium channel but not other common receptors. The exact mechanism by which it treats RLS or manages PHN is unknown, they write.
Gabapentin enacarbil (Horizant)
"Horizant is not interchangeable with other gabapentin products because of differing pharmacokinetic profiles," the statement points out. "The same dose of Horizant results in different plasma concentrations of gabapentin relative to the same dose of other gabapentin products."
The efficacy and safety of the drug in the setting of PHN was evaluated in a 12-week principal efficacy trial, along with 2 supportive studies that all met their primary endpoints. The 3 studies included 574 adult patients from the United States, Canada, and Germany.
In the 12-week controlled study, the most frequently reported side effects were somnolence and dizziness: somnolence was reported in 10% of those taking 1200 mg of gabapentin enacarbil per day vs 8% of those receiving placebo; and dizziness was reported by 17% of treated patients vs 15% of those taking placebo. Headache occurred in 10% and 9%, respectively; nausea in 8% vs 5% of placebo patients; and fatigue/asthenia in 6% of treated patients vs 1% of placebo patients.
Initiation of treatment should be at a dose of 600 mg in the morning for 3 days, followed by the recommended full dose of 600 mg twice daily (1200 mg per day) beginning on day 4, they note. Doses must be adjusted in patients with impaired renal function.
Postherpetic neuralgia occurs in about 10% of those recovering from an outbreak of herpes zoster, commonly known as shingles.
The statement includes the following safety information:
  • Effects on driving: The drug causes significant driving impairment, and treated patients "should not drive until they have sufficient experience to know whether their ability to drive is impaired." The patient's own ability to assess their driving competence and the degree of somnolence caused by the drug "can be imperfect," they note.
  • Suicidal behavior and ideation: Gabapentin enacarbil is a prodrug of gabapentin, an antiepileptic drug (AED). AEDs increase the risk of suicidal thoughts or ideation, and as a prodrug of gabapentin, gabapentin enacarbil also increases this risk. Patients should be monitored for new or worsening depression, suicidal thoughts or behavior, or any unusual changes in mood or behavior. Patients, caregivers, and their families should be advised of this risk and report any behaviors of concern to their healthcare provider. "Anyone considering prescribing Horizant must balance the risk of suicidal thoughts or behavior with the risk of untreated illness," the statement notes.
The safety and effectiveness of gabapentin enacarbil has not been studied in patients with epilepsy.
  • Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity: This condition has been reported with other AEDs and is a risk with this new agent; some events have been fatal or life-threatening.
"DRESS typically, although not exclusively, presents with fever, rash and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis, sometimes resembling an acute viral infection," the statement notes. "Eosinophilia is often present. Because the disorder is variable in its expression, other organ systems not noted here may be involved."
  • Discontinuation: In patients with PHN receiving gabapentin enacarbil twice daily, the dose should be reduced to once-daily for 1 week prior to discontinuation to minimize the potential for withdrawal seizure.
Complete prescribing information is available at www.gsk.com.
Gabapentin enacarbil is not approved outside of the United States for this indication. It is also approved for moderate to severe RLS in adults but is not recommended for those who need to sleep during the day and remain awake at night.
Horizant is a registered US trademark of GSK. In association with GSK's first commercial sale of the product after approval for PHN, XenoPort is entitled to a milestone payment of $10 million from GSK.

Comments

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to

FDA Approves First Pill for Heavy Menstrual Bleeding

March 16, 2012 — Estradiol valerate and estradiol valerate/dienogest ( Natazia , Bayer HealthCare Pharmaceuticals Inc) oral contraceptive tablets were approved March 14 for the treatment of heavy menstrual bleeding (HMB). According to a company press release, this agent is the first and only oral contraceptive indicated for the treatment of HMB. The drug was approved in May 2010 for the prevention of pregnancy. The current approval was based on results from 2 multicenter, randomized, double-blind, placebo-controlled clinical trials including 421 women. Women in the study were at least 18 years of age and were diagnosed with dysfunctional uterine bleeding, described as heavy, prolonged and/or frequent, and without organic pathology. HMB was defined as "menstrual blood loss of 80 mL or more in at least 2 bleeding episodes during a 90-day run in phase." Patients were randomly assigned to receive either treatment or placebo for 7 menstrual cycles. Complete symptom relief dur